{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tesamorelin-postherpetic","title":"Tesamorelin for Postherpetic Neuralgia: Evidence Review","body":"## What's breaking down\n\nPostherpetic neuralgia (PHN) follows shingles (herpes zoster) reactivation of varicella-zoster virus. Nerve damage occurs in affected dermatomes. Axons degenerate. Myelin sheaths suffer. Distal tissues lose innervation. Muscle atrophy can follow if reinnervation lags. Chronic pain persists because repair pathways fail to restore normal signaling. This is degeneration outrunning repair at the peripheral nerve level.\n\n## Why Tesamorelin might help you\n\nTesamorelin stimulates growth hormone release via the GH axis. If your postherpetic issue includes failed axonal regeneration or muscle atrophy from denervation, this layer matters.\n\n1. GH and IGF-1 signaling support Schwann cell activity and axon growth in nerve injury models.\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n3. Reduced visceral fat is a separate documented effect but not directly tied to neural recovery here.\n\n## How these fit together\n\nSingle-compound focus. Tesamorelin maps to the GH axis / visceral fat layer. If your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n\n- **Tesamorelin** → GH axis / visceral fat\n\n## What the evidence actually shows\n\nNo human trials test tesamorelin specifically in postherpetic neuralgia (preclinical|mechanistic). One ongoing Phase 2 trial (NCT03150511) evaluates tesamorelin after peripheral nerve injury repair in humans; outcomes include axonal regeneration via MRI/EMG and functional recovery. Results remain unpublished as of 2026 (human|ongoing).\n\nAnimal studies show growth hormone improves sciatic nerve regeneration after transection in rats: increased axon and Schwann cell density, higher compound muscle action potential amplitude, and better treadmill performance (preclinical|animal).\n\nA 2016 review summarizes GH/IGF-1 effects on multiple tissues in peripheral nerve injury, including reduced muscle atrophy (preclinical|review).\n\nTesamorelin reduces visceral adipose tissue in HIV patients per prior FDA data, but this does not address nerve repair (human|separate indication).\n\n## What scientists say\n\nResearchers note GH-based therapies show multi-modal promise for peripheral nerve injuries through accelerated regeneration and atrophy limitation, distinct from single-pathway agents (mechanistic|review). They call for clinical translation but emphasize lack of approved indications for neuropathic pain syndromes like PHN.\n\n## What people say on Reddit\n\nScant discussion. One thread mentions thymosin peptides for potential nerve repair in PHN contexts; no direct tesamorelin reports (anecdotal|none).\n\n## What people say on X\n\nNo relevant posts identified linking tesamorelin to postherpetic neuralgia or shingles recovery (anecdotal|none).\n\n## What we do not know\n\nDirect efficacy in PHN remains untested in humans. Optimal timing post-shingles, interaction with standard analgesics, and long-term nerve-specific outcomes lack data. Translation from traumatic nerve injury models to viral neuropathy is speculative.\n\n## Safety and limits\n\nTesamorelin carries documented effects on glucose metabolism and injection-site reactions from approved use. No PHN-specific safety data exist. Evidence base is early-stage for nerve applications overall.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-postherpetic/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No human trials test tesamorelin specifically in postherpetic neuralgia.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes evidence gap for this exact condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Ongoing Phase 2 trial NCT03150511 tests tesamorelin after peripheral nerve injury repair for axonal regeneration and functional recovery.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Closest human data point on nerve repair.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"GH treatment in rats after sciatic nerve transection increased axon/Schwann cell density and improved functional measures.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Supports regeneration mechanism in animal models.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"GH/IGF-1 therapies show multi-modal effects on nerve regeneration and muscle preservation in peripheral nerve injury reviews.","section":"What scientists say","tier":"mechanistic","source_ids":["s4"],"source_status":"sourced","why_material":"Explains proposed repair pathway.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","summary":"Ongoing trial focused on PNI, not PHN.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:15:58.623Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"0bb8ee52ed18044671c3b1d8be7435b69942c9bfb12188f9c6aed8e493b8e206"},{"id":"s2","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The investigators hypothesize that treatment with tesamorelin will result in faster and more substantial recovery of motor and sensory function following surgical repair of injured peripheral nerves.","summary":"Details trial aims for nerve recovery.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:15:58.623Z","link_status":"ok","quote_status":"unverified","prev":"0bb8ee52ed18044671c3b1d8be7435b69942c9bfb12188f9c6aed8e493b8e206","hash":"5cf2d75bebd4cb6fcd0054e01b88141694d91834b1adb8b7595bfaab6fd68979"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22334173/","title":"Growth hormone treatment enhances the functional recovery of sciatic nerves after transection and repair","quote":"GH-treated rats showed increased cellularity at the lesion site together with more abundant immunoreactive axons and Schwann cells.","summary":"Rat study on GH for nerve repair.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:15:58.623Z","link_status":"ok","quote_status":"verified","prev":"5cf2d75bebd4cb6fcd0054e01b88141694d91834b1adb8b7595bfaab6fd68979","hash":"7a65c15798ff045d4a823a17e55ef7186488ccc94aee1af4ee466faa052444e3"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/27192539/","title":"Therapeutic augmentation of the growth hormone axis to enhance peripheral nerve regeneration","quote":"GH-based therapies carry great promise for the treatment of peripheral nerve injuries, given the multi-modal mechanism of action not seen with other experimental therapies.","summary":"Review of GH mechanisms in nerve injury.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:15:58.623Z","link_status":"ok","quote_status":"verified","prev":"7a65c15798ff045d4a823a17e55ef7186488ccc94aee1af4ee466faa052444e3","hash":"9063649e77acdc096593f57d922135ad5a0d5750117d8b5393c7ed433f080f56"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:15:59.416Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Postherpetic Neuralgia: Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nPostherpetic neuralgia (PHN) follows shingles (herpes zoster) reactivation of varicella-zoster virus. Nerve damage occurs in affected dermatomes. Axons degenerate. Myelin sheaths suffer. Distal tissues lose innervation. Muscle atrophy can follow if reinnervation lags. Chronic pain persists because repair pathways fail to restore normal signaling. This is degeneration outrunning repair at the peripheral nerve level.\n\n## Why Tesamorelin might help you\n\nTesamorelin stimulates growth hormone release via the GH axis. If your postherpetic issue includes failed axonal regeneration or muscle atrophy from denervation, this layer matters.\n\n1. GH and IGF-1 signaling support Schwann cell activity and axon growth in nerve injury models.\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n3. Reduced visceral fat is a separate documented effect but not directly tied to neural recovery here.\n\n## How these fit together\n\nSingle-compound focus. Tesamorelin maps to the GH axis / visceral fat layer. If your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n\n- **Tesamorelin** → GH axis / visceral fat\n\n## What the evidence actually shows\n\nNo human trials test tesamorelin specifically in postherpetic neuralgia (preclinical|mechanistic). One ongoing Phase 2 trial (NCT03150511) evaluates tesamorelin after peripheral nerve injury repair in humans; outcomes include axonal regeneration via MRI/EMG and functional recovery. Results remain unpublished as of 2026 (human|ongoing).\n\nAnimal studies show growth hormone improves sciatic nerve regeneration after transection in rats: increased axon and Schwann cell density, higher compound muscle action potential amplitude, and better treadmill performance (preclinical|animal).\n\nA 2016 review summarizes GH/IGF-1 effects on multiple tissues in peripheral nerve injury, including reduced muscle atrophy (preclinical|review).\n\nTesamorelin reduces visceral adipose tissue in HIV patients per prior FDA data, but this does not address nerve repair (human|separate indication).\n\n## What scientists say\n\nResearchers note GH-based therapies show multi-modal promise for peripheral nerve injuries through accelerated regeneration and atrophy limitation, distinct from single-pathway agents (mechanistic|review). They call for clinical translation but emphasize lack of approved indications for neuropathic pain syndromes like PHN.\n\n## What people say on Reddit\n\nScant discussion. One thread mentions thymosin peptides for potential nerve repair in PHN contexts; no direct tesamorelin reports (anecdotal|none).\n\n## What people say on X\n\nNo relevant posts identified linking tesamorelin to postherpetic neuralgia or shingles recovery (anecdotal|none).\n\n## What we do not know\n\nDirect efficacy in PHN remains untested in humans. Optimal timing post-shingles, interaction with standard analgesics, and long-term nerve-specific outcomes lack data. Translation from traumatic nerve injury models to viral neuropathy is speculative.\n\n## Safety and limits\n\nTesamorelin carries documented effects on glucose metabolism and injection-site reactions from approved use. No PHN-specific safety data exist. Evidence base is early-stage for nerve applications overall.","claims":[{"id":"c1","text":"No human trials test tesamorelin specifically in postherpetic neuralgia.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes evidence gap for this exact condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Ongoing Phase 2 trial NCT03150511 tests tesamorelin after peripheral nerve injury repair for axonal regeneration and functional recovery.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Closest human data point on nerve repair.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"GH treatment in rats after sciatic nerve transection increased axon/Schwann cell density and improved functional measures.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Supports regeneration mechanism in animal models.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"GH/IGF-1 therapies show multi-modal effects on nerve regeneration and muscle preservation in peripheral nerve injury reviews.","section":"What scientists say","tier":"mechanistic","source_ids":["s4"],"source_status":"sourced","why_material":"Explains proposed repair pathway.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The investigators hypothesize that treatment with tesamorelin will result in faster and more substantial recovery of motor and sensory function following surgical repair of injured peripheral nerves.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22334173/","title":"Growth hormone treatment enhances the functional recovery of sciatic nerves after transection and repair","quote":"GH-treated rats showed increased cellularity at the lesion site together with more abundant immunoreactive axons and Schwann cells.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/27192539/","title":"Therapeutic augmentation of the growth hormone axis to enhance peripheral nerve regeneration","quote":"GH-based therapies carry great promise for the treatment of peripheral nerve injuries, given the multi-modal mechanism of action not seen with other experimental therapies.","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":28024,"tokens_out":2600,"cost":0.04153,"prev_hash":"genesis","hash":"bdc9116903e37af95515e6cef8ae39551779c976d0dd675880b54f7370db59e6"}],"provenance":[{"ts":"2026-06-29T23:15:59.416Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Postherpetic\nSlug: tesamorelin-postherpetic\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down\",\"Why Tesamorelin might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one pe","response":"{\n  \"slug\": \"tesamorelin-postherpetic\",\n  \"title\": \"Tesamorelin for Postherpetic Neuralgia: Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nPostherpetic neuralgia (PHN) follows shingles (herpes zoster) reactivation of varicella-zoster virus. Nerve damage occurs in affected dermatomes. Axons degenerate. Myelin sheaths suffer. Distal tissues lose innervation. Muscle atrophy can follow if reinnervation lags. Chronic pain persists because repair pathways fail to restore normal signaling. This is degeneration outrunning repair at the peripheral nerve level.\\n\\n## Why Tesamorelin might help you\\n\\nTesamorelin stimulates growth hormone release via the GH axis. If your postherpetic issue includes failed axonal regeneration or muscle atrophy from denervation, this layer matters.\\n\\n1. GH and IGF-1 signaling support Schwann cell activity and axon growth in nerve injury models.\\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\\n3. Reduced visceral fat is a separate documented effect but not directly tied to neural recovery here.\\n\\n## How these fit together\\n\\nSingle-compound focus. Tesamorelin maps to the GH axis / visceral fat layer. If your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n\\n- **Tesamorelin** → GH axis / visceral fat\\n\\n## What the evidence actually shows\\n\\nNo human trials test tesamorelin specifically in postherpetic neuralgia (preclinical|mechanistic). One ongoing Phase 2 trial (NCT03150511) evaluates tesamorelin after peripheral nerve injury repair in humans; outcomes include axonal regeneration via MRI/EMG and functional recovery. Results remain unpublished as of 2026 (human|ongoing).\\n\\nAnimal studies show growth hormone improves sciatic nerve regeneration after transection in rats: increased axon and Schwann cell density, higher compound muscle action potential amplitude, and bette","tokens_in":28024,"tokens_out":2600,"cost":0,"prev":"genesis","hash":"6043c17c1a0ea584e53d729c9f9c0d8b6cdc25ed33e58c8867ac7027e45a6a6b"},{"ts":"2026-07-17T02:42:25.507Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-postherpetic","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6043c17c1a0ea584e53d729c9f9c0d8b6cdc25ed33e58c8867ac7027e45a6a6b","hash":"bc4c6e4e64b228f9121e5a89e74158b5c7616fb7e31d27f3b1f18df1e1295ab4"}],"energy":{"passes":2,"tokens_in":28024,"tokens_out":2600,"tokens_total":30624,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"bc4c6e4e64b228f9121e5a89e74158b5c7616fb7e31d27f3b1f18df1e1295ab4"},"posted_at":"2026-06-29T21:33:35.112Z","created_at":"2026-06-29T21:33:35.112Z","updated_at":"2026-07-17T02:42:25.507Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-postherpetic","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-postherpetic","json":"https://miscsubjects.com/api/articles/tesamorelin-postherpetic","bundle":"https://miscsubjects.com/api/articles/tesamorelin-postherpetic/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-postherpetic/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-postherpetic","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-postherpetic\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-postherpetic\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-postherpetic/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-postherpetic\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-postherpetic | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-postherpetic","json":"/api/articles/tesamorelin-postherpetic","markdown":"/api/articles/tesamorelin-postherpetic/bundle?format=markdown","skill":"/api/articles/tesamorelin-postherpetic/skill","topology":"/api/articles/tesamorelin-postherpetic/topology","versions":"/api/articles/tesamorelin-postherpetic/revisions","invocations":"/api/articles/tesamorelin-postherpetic/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-postherpetic","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"3adac43ea6935063df4a569010277ac4a299c34f52669538209bf2310383d844","object":{"object_type":"article-object","identity":{"id":"article:tesamorelin-postherpetic","slug":"tesamorelin-postherpetic","title":"Tesamorelin for Postherpetic Neuralgia: Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tesamorelin-postherpetic","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tesamorelin-postherpetic/skill","role":"direct behavior","audience":"model","content":"---\nname: tesamorelin-postherpetic\ndescription: Apply the Tesamorelin for Postherpetic Neuralgia: Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Tesamorelin for Postherpetic Neuralgia: Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/tesamorelin-postherpetic). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tesamorelin-postherpetic.\n- Read claims and relationships at /api/articles/tesamorelin-postherpetic/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Postherpetic neuralgia PHN follows shingles herpes zoster reactivation of varicella-zoster virus. Nerve damage occurs in affected dermatomes. Axons degenerate. Myelin sheaths suffer. Distal tissues lose innervation. Mus\n\n## Representations\n\n- Human: /a/tesamorelin-postherpetic\n- JSON: /api/articles/tesamorelin-postherpetic\n- Relationships: /api/articles/tesamorelin-postherpetic/topology\n- History: /api/articles/tesamorelin-postherpetic/revisions\n"},"json":{"route":"/api/articles/tesamorelin-postherpetic","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tesamorelin-postherpetic/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tesamorelin","postherpetic"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tesamorelin-postherpetic/invocations?status=success","failure_events":"/api/articles/tesamorelin-postherpetic/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tesamorelin-postherpetic","title":"Tesamorelin for Postherpetic Neuralgia: Evidence Review","body":"## What's breaking down\n\nPostherpetic neuralgia (PHN) follows shingles (herpes zoster) reactivation of varicella-zoster virus. Nerve damage occurs in affected dermatomes. Axons degenerate. Myelin sheaths suffer. Distal tissues lose innervation. Muscle atrophy can follow if reinnervation lags. Chronic pain persists because repair pathways fail to restore normal signaling. This is degeneration outrunning repair at the peripheral nerve level.\n\n## Why Tesamorelin might help you\n\nTesamorelin stimulates growth hormone release via the GH axis. If your postherpetic issue includes failed axonal regeneration or muscle atrophy from denervation, this layer matters.\n\n1. GH and IGF-1 signaling support Schwann cell activity and axon growth in nerve injury models.\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n3. Reduced visceral fat is a separate documented effect but not directly tied to neural recovery here.\n\n## How these fit together\n\nSingle-compound focus. Tesamorelin maps to the GH axis / visceral fat layer. If your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n\n- **Tesamorelin** → GH axis / visceral fat\n\n## What the evidence actually shows\n\nNo human trials test tesamorelin specifically in postherpetic neuralgia (preclinical|mechanistic). One ongoing Phase 2 trial (NCT03150511) evaluates tesamorelin after peripheral nerve injury repair in humans; outcomes include axonal regeneration via MRI/EMG and functional recovery. Results remain unpublished as of 2026 (human|ongoing).\n\nAnimal studies show growth hormone improves sciatic nerve regeneration after transection in rats: increased axon and Schwann cell density, higher compound muscle action potential amplitude, and better treadmill performance (preclinical|animal).\n\nA 2016 review summarizes GH/IGF-1 effects on multiple tissues in peripheral nerve injury, including reduced muscle atrophy (preclinical|review).\n\nTesamorelin reduces visceral adipose tissue in HIV patients per prior FDA data, but this does not address nerve repair (human|separate indication).\n\n## What scientists say\n\nResearchers note GH-based therapies show multi-modal promise for peripheral nerve injuries through accelerated regeneration and atrophy limitation, distinct from single-pathway agents (mechanistic|review). They call for clinical translation but emphasize lack of approved indications for neuropathic pain syndromes like PHN.\n\n## What people say on Reddit\n\nScant discussion. One thread mentions thymosin peptides for potential nerve repair in PHN contexts; no direct tesamorelin reports (anecdotal|none).\n\n## What people say on X\n\nNo relevant posts identified linking tesamorelin to postherpetic neuralgia or shingles recovery (anecdotal|none).\n\n## What we do not know\n\nDirect efficacy in PHN remains untested in humans. Optimal timing post-shingles, interaction with standard analgesics, and long-term nerve-specific outcomes lack data. Translation from traumatic nerve injury models to viral neuropathy is speculative.\n\n## Safety and limits\n\nTesamorelin carries documented effects on glucose metabolism and injection-site reactions from approved use. No PHN-specific safety data exist. Evidence base is early-stage for nerve applications overall.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-postherpetic/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No human trials test tesamorelin specifically in postherpetic neuralgia.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes evidence gap for this exact condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Ongoing Phase 2 trial NCT03150511 tests tesamorelin after peripheral nerve injury repair for axonal regeneration and functional recovery.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Closest human data point on nerve repair.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"GH treatment in rats after sciatic nerve transection increased axon/Schwann cell density and improved functional measures.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Supports regeneration mechanism in animal models.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"GH/IGF-1 therapies show multi-modal effects on nerve regeneration and muscle preservation in peripheral nerve injury reviews.","section":"What scientists say","tier":"mechanistic","source_ids":["s4"],"source_status":"sourced","why_material":"Explains proposed repair pathway.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","summary":"Ongoing trial focused on PNI, not PHN.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:15:58.623Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"0bb8ee52ed18044671c3b1d8be7435b69942c9bfb12188f9c6aed8e493b8e206"},{"id":"s2","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The investigators hypothesize that treatment with tesamorelin will result in faster and more substantial recovery of motor and sensory function following surgical repair of injured peripheral nerves.","summary":"Details trial aims for nerve recovery.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:15:58.623Z","link_status":"ok","quote_status":"unverified","prev":"0bb8ee52ed18044671c3b1d8be7435b69942c9bfb12188f9c6aed8e493b8e206","hash":"5cf2d75bebd4cb6fcd0054e01b88141694d91834b1adb8b7595bfaab6fd68979"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22334173/","title":"Growth hormone treatment enhances the functional recovery of sciatic nerves after transection and repair","quote":"GH-treated rats showed increased cellularity at the lesion site together with more abundant immunoreactive axons and Schwann cells.","summary":"Rat study on GH for nerve repair.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:15:58.623Z","link_status":"ok","quote_status":"verified","prev":"5cf2d75bebd4cb6fcd0054e01b88141694d91834b1adb8b7595bfaab6fd68979","hash":"7a65c15798ff045d4a823a17e55ef7186488ccc94aee1af4ee466faa052444e3"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/27192539/","title":"Therapeutic augmentation of the growth hormone axis to enhance peripheral nerve regeneration","quote":"GH-based therapies carry great promise for the treatment of peripheral nerve injuries, given the multi-modal mechanism of action not seen with other experimental therapies.","summary":"Review of GH mechanisms in nerve injury.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:15:58.623Z","link_status":"ok","quote_status":"verified","prev":"7a65c15798ff045d4a823a17e55ef7186488ccc94aee1af4ee466faa052444e3","hash":"9063649e77acdc096593f57d922135ad5a0d5750117d8b5393c7ed433f080f56"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:15:59.416Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Postherpetic Neuralgia: Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nPostherpetic neuralgia (PHN) follows shingles (herpes zoster) reactivation of varicella-zoster virus. Nerve damage occurs in affected dermatomes. Axons degenerate. Myelin sheaths suffer. Distal tissues lose innervation. Muscle atrophy can follow if reinnervation lags. Chronic pain persists because repair pathways fail to restore normal signaling. This is degeneration outrunning repair at the peripheral nerve level.\n\n## Why Tesamorelin might help you\n\nTesamorelin stimulates growth hormone release via the GH axis. If your postherpetic issue includes failed axonal regeneration or muscle atrophy from denervation, this layer matters.\n\n1. GH and IGF-1 signaling support Schwann cell activity and axon growth in nerve injury models.\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n3. Reduced visceral fat is a separate documented effect but not directly tied to neural recovery here.\n\n## How these fit together\n\nSingle-compound focus. Tesamorelin maps to the GH axis / visceral fat layer. If your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n\n- **Tesamorelin** → GH axis / visceral fat\n\n## What the evidence actually shows\n\nNo human trials test tesamorelin specifically in postherpetic neuralgia (preclinical|mechanistic). One ongoing Phase 2 trial (NCT03150511) evaluates tesamorelin after peripheral nerve injury repair in humans; outcomes include axonal regeneration via MRI/EMG and functional recovery. Results remain unpublished as of 2026 (human|ongoing).\n\nAnimal studies show growth hormone improves sciatic nerve regeneration after transection in rats: increased axon and Schwann cell density, higher compound muscle action potential amplitude, and better treadmill performance (preclinical|animal).\n\nA 2016 review summarizes GH/IGF-1 effects on multiple tissues in peripheral nerve injury, including reduced muscle atrophy (preclinical|review).\n\nTesamorelin reduces visceral adipose tissue in HIV patients per prior FDA data, but this does not address nerve repair (human|separate indication).\n\n## What scientists say\n\nResearchers note GH-based therapies show multi-modal promise for peripheral nerve injuries through accelerated regeneration and atrophy limitation, distinct from single-pathway agents (mechanistic|review). They call for clinical translation but emphasize lack of approved indications for neuropathic pain syndromes like PHN.\n\n## What people say on Reddit\n\nScant discussion. One thread mentions thymosin peptides for potential nerve repair in PHN contexts; no direct tesamorelin reports (anecdotal|none).\n\n## What people say on X\n\nNo relevant posts identified linking tesamorelin to postherpetic neuralgia or shingles recovery (anecdotal|none).\n\n## What we do not know\n\nDirect efficacy in PHN remains untested in humans. Optimal timing post-shingles, interaction with standard analgesics, and long-term nerve-specific outcomes lack data. Translation from traumatic nerve injury models to viral neuropathy is speculative.\n\n## Safety and limits\n\nTesamorelin carries documented effects on glucose metabolism and injection-site reactions from approved use. No PHN-specific safety data exist. Evidence base is early-stage for nerve applications overall.","claims":[{"id":"c1","text":"No human trials test tesamorelin specifically in postherpetic neuralgia.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes evidence gap for this exact condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Ongoing Phase 2 trial NCT03150511 tests tesamorelin after peripheral nerve injury repair for axonal regeneration and functional recovery.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Closest human data point on nerve repair.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"GH treatment in rats after sciatic nerve transection increased axon/Schwann cell density and improved functional measures.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Supports regeneration mechanism in animal models.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"GH/IGF-1 therapies show multi-modal effects on nerve regeneration and muscle preservation in peripheral nerve injury reviews.","section":"What scientists say","tier":"mechanistic","source_ids":["s4"],"source_status":"sourced","why_material":"Explains proposed repair pathway.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:15:59.011Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The investigators hypothesize that treatment with tesamorelin will result in faster and more substantial recovery of motor and sensory function following surgical repair of injured peripheral nerves.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22334173/","title":"Growth hormone treatment enhances the functional recovery of sciatic nerves after transection and repair","quote":"GH-treated rats showed increased cellularity at the lesion site together with more abundant immunoreactive axons and Schwann cells.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/27192539/","title":"Therapeutic augmentation of the growth hormone axis to enhance peripheral nerve regeneration","quote":"GH-based therapies carry great promise for the treatment of peripheral nerve injuries, given the multi-modal mechanism of action not seen with other experimental therapies.","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":28024,"tokens_out":2600,"cost":0.04153,"prev_hash":"genesis","hash":"bdc9116903e37af95515e6cef8ae39551779c976d0dd675880b54f7370db59e6"}],"provenance":[{"ts":"2026-06-29T23:15:59.416Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Postherpetic\nSlug: tesamorelin-postherpetic\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down\",\"Why Tesamorelin might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one pe","response":"{\n  \"slug\": \"tesamorelin-postherpetic\",\n  \"title\": \"Tesamorelin for Postherpetic Neuralgia: Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nPostherpetic neuralgia (PHN) follows shingles (herpes zoster) reactivation of varicella-zoster virus. Nerve damage occurs in affected dermatomes. Axons degenerate. Myelin sheaths suffer. Distal tissues lose innervation. Muscle atrophy can follow if reinnervation lags. Chronic pain persists because repair pathways fail to restore normal signaling. This is degeneration outrunning repair at the peripheral nerve level.\\n\\n## Why Tesamorelin might help you\\n\\nTesamorelin stimulates growth hormone release via the GH axis. If your postherpetic issue includes failed axonal regeneration or muscle atrophy from denervation, this layer matters.\\n\\n1. GH and IGF-1 signaling support Schwann cell activity and axon growth in nerve injury models.\\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\\n3. Reduced visceral fat is a separate documented effect but not directly tied to neural recovery here.\\n\\n## How these fit together\\n\\nSingle-compound focus. Tesamorelin maps to the GH axis / visceral fat layer. If your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n\\n- **Tesamorelin** → GH axis / visceral fat\\n\\n## What the evidence actually shows\\n\\nNo human trials test tesamorelin specifically in postherpetic neuralgia (preclinical|mechanistic). One ongoing Phase 2 trial (NCT03150511) evaluates tesamorelin after peripheral nerve injury repair in humans; outcomes include axonal regeneration via MRI/EMG and functional recovery. Results remain unpublished as of 2026 (human|ongoing).\\n\\nAnimal studies show growth hormone improves sciatic nerve regeneration after transection in rats: increased axon and Schwann cell density, higher compound muscle action potential amplitude, and bette","tokens_in":28024,"tokens_out":2600,"cost":0,"prev":"genesis","hash":"6043c17c1a0ea584e53d729c9f9c0d8b6cdc25ed33e58c8867ac7027e45a6a6b"},{"ts":"2026-07-17T02:42:25.507Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-postherpetic","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6043c17c1a0ea584e53d729c9f9c0d8b6cdc25ed33e58c8867ac7027e45a6a6b","hash":"bc4c6e4e64b228f9121e5a89e74158b5c7616fb7e31d27f3b1f18df1e1295ab4"}],"energy":{"passes":2,"tokens_in":28024,"tokens_out":2600,"tokens_total":30624,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"bc4c6e4e64b228f9121e5a89e74158b5c7616fb7e31d27f3b1f18df1e1295ab4"},"posted_at":"2026-06-29T21:33:35.112Z","created_at":"2026-06-29T21:33:35.112Z","updated_at":"2026-07-17T02:42:25.507Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-postherpetic","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-postherpetic","json":"https://miscsubjects.com/api/articles/tesamorelin-postherpetic","bundle":"https://miscsubjects.com/api/articles/tesamorelin-postherpetic/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-postherpetic/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-postherpetic","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-postherpetic\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-postherpetic\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-postherpetic/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-postherpetic\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-postherpetic | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-postherpetic","json":"/api/articles/tesamorelin-postherpetic","markdown":"/api/articles/tesamorelin-postherpetic/bundle?format=markdown","skill":"/api/articles/tesamorelin-postherpetic/skill","topology":"/api/articles/tesamorelin-postherpetic/topology","versions":"/api/articles/tesamorelin-postherpetic/revisions","invocations":"/api/articles/tesamorelin-postherpetic/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-postherpetic","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"3adac43ea6935063df4a569010277ac4a299c34f52669538209bf2310383d844"}}}